Maike Pharmaceutical-B (02335.HK): Preclinical and Phase I clinical data of MT200605 accepted for oral presentation at the 18th World Stroke Congress in 2026

Zhiying Finance APP news, Mai Ke Medicine-B (02335.HK) announced that the preclinical and Phase I clinical data of its self-developed injectable neuroprotective candidate drug MT200605 for the treatment of acute ischemic stroke (AIS) have been accepted for oral presentation at the 18th World Stroke Congress (WSC 2026).